This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Office of Drug Control (ODC) issues several license types, including: Cultivation growing cannabis for medicinal or research purposes. Research studying cannabis for medicinal development. Businesses should also investigate potential research and development (R&D) incentives if applicable.
SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.
Shanita Penny, President of the Minority Cannabis Business Association (MCBA) said , “The Ending Federal Marijuana Prohibition Act of 2019 removes a roadblock impeding criminal justice reform, patient and consumer access, research and innovation.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
Our outdated laws have ruined lives, devastated communities, and wasted resources for critical medical treatment and research. The enactment of these policies have not negatively impacted workplace safety , crime rates , traffic safety , or youth use patterns. ” Said Rep.
From 1994 to 2013, he was employed as a principal investigator at DuPont Central Research and Development. with unknown pharmacological and safety profiles.” End cannabis prohibition, the market for these products will go away and these compounds will be relegated to research labs, where they belong, not the marketplace.
NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.
Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Legislation is pending, HB 350, to expand medical cannabis access. NH resident? GA resident?
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.
Biotech startup to bring safety and efficacy to the emerging psychedelic industry, brings on University of Michigan Researcher as Chief Science Officer. Nearly all forms of research being done on psychedelics are via the digestive tract, which slows uptake, requires higher dosage, and may lead to harmful side effects in the body.
We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. We are in a mental health crisis and its critical to ensure that we conduct clinical trials to demonstrate safety, and efficacy up to and including phase 3 large scale clinical trials.
The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.
We’ve got an update on the latest Montana legalization developments. The news on access to loans and other support from the Small Business Administration was less rosy. marijuana research. The group promises to follow safety protocols, so they can muster the support they need, without risking anyone’s health.
West Virginia’s medical marijuana program was established to provide patients with qualifying medical conditions access to medical cannabis as an alternative treatment option. In this guide, we’ll break down everything you need to know to start accessing medical marijuana in West Virginia.
At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. The company is scaling its proprietary research and development methods in order to become one of the first to produce and bring to market psilocybin-based treatments.
Though the distinction between these terms may seem trivial at first glance, it is in fact crucial for cannabis research, and therefore also for consumers and regulators as well. Researchers conducting survey based studies today often only have access to the THC concentration of the cannabis that their participants are using.
New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. Cannabis’ Place in Substance Abuse Recovery .
TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers.
Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Validcare contracted with 17 CBD companies and acted as the Contract Research Organization, which included gaining feedback from FDA on the protocol, conducting the study and publishing its results.
NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study abstract is available here. The methods for both phases were the same.
–(BUSINESS WIRE)– PSI Labs , an Ann Arbor, Michigan-based ISO 17025 accredited Safety Compliance Facility that provides essential cannabis testing services, today announced its expansion into Southern California with the acquisition of pH Solutions, LLC. Monrovia-Based Lab Acquisition Strengthens Cannabis Testing In California.
Additionally, no current treatments can reverse existing neurological damage, highlighting the need for ongoing research into more effective therapies and potential cures. Clinical Evidence and Research Findings Research into the efficacy of medical marijuana for MS management has yielded promising results.
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.
The UK is a significant country for us for many reasons, and we are proud to be able to offer a medicine, that has been developed and is manufactured here, to even more patients across the UK. The safety profile observed was consistent with findings from previous studies, with no new safety risks identified.
Ethics, Safety, and Abuse in Psychedelic Medicine. As psychedelic medicine becomes more mainstream, we must ensure that all who participate in healing therapeutic sessions, both above ground and in ceremonial or underground therapeutic settings, are safe and accessible to all. Wednesday, December 8th from 12:00-2:00pm PST.
Our goal is to leverage the election period to encourage more License Holders to develop lasting relationships with their local Member of Parliament and to help elected officials understand the benefits of legal cannabis for their communities and their constituents” he added. Materials will be easy to access, downloadable and customizable.
Economic Growth and Job Creation of the medical marijuana industry The medical cannabis sector serves as a catalyst for economic expansion and workforce development in regions where it’s legalized. Moreover, ensuring product quality and safety throughout the supply chain is paramount to maintain patient trust and regulatory compliance.
The Board will also develop a long-term strategic plan for ensuring that psilocybin services will become and remain a safe, accessible and affordable therapeutic option for all persons 21 years of age and older in this state for whom psilocybin may be appropriate and monitor and study federal laws, regulations and policies regarding psilocybin.
At the end of November 2021, the CDC’s National Institute for Occupational Safety and Health (NIOSH) announced that there are deep-seated risks associated with driving a motor vehicle under the influence of cannabis’ psychotropic compound tetrahydrocannabinol (THC). Because marijuana use is on the rise for adults in the U.S.,
The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they developsafety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.
Producing deep-dive policy and operational research and analysis on priority initiatives. Translating complex policy ideas into talking points, emails, briefs, and other publicly accessible communications. Assist in the research, drafting, and creation of policies for the Supervisor.
Delic Labs’ latest exemptions enable the Company to develop innovative analytical methods for psychedelic research. Last year, the lab also applied for a Dealer’s License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes.
By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies.
Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. But if that doctor has access to information from 40,000 patients it’s a different story. The Upshot.
Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK. Partnership being developed to accelerate psychedelic research and develop new models of mental health care in the UK. LONDON, Aug. million, or $0.79
This number also underscores the entire agency’s tireless efforts, particularly those of our hardworking staff, to thoughtfully regulate a safe, accessible, and effective adult-use marketplace that keeps critical tenets of our mission – public health, public safety, and equity, among others – front of mind.”.
Virginia is committed to legalizing cannabis the right way—by learning from other states, by listening to public health and safety experts, and by centering social equity,” said Governor Northam. On July 1, recreational marijuana became legal for adult use in Virginia. Board members cannot have financial interests in the cannabis industry.
The board will work on projects like designing the training program for psychedelic facilitators, tracking psychedelic policy development, studying ongoing science related to psilocybin, and making recommendations to lawmakers regarding the bill. People will not have to meet specific qualifications to access care.
We take a look at where CBD regulation might be going and whether we should be concerned about safety writes Rob Verkerk PhD, scientific and executive director, ANH-Intl. We take a look at where CBD regulation might be going and whether we should be concerned about safety. A new ‘problem’: safety. ? A new ‘problem’: safety.
If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. Research and Testimonials Point to Psychedelics’ Therapeutic Benefits.
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.
On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content